SCHEDULE: ADAR1 Capital Management Exits Stake in OnKure Therapeutics

ADAR1 Capital Management, LLC and related entities have filed a Schedule 13G amendment, reporting a reduction in their beneficial ownership of OnKure Therapeutics, Inc. Class A Common Stock.

Summary

• ADAR1 Capital Management, LLC, ADAR1 Capital Management GP, LLC, and Daniel Schneeberger have filed an amendment to their Schedule 13G.
• This filing indicates an exit for ADAR1 Capital Management GP, LLC from its reporting obligations.
• As of June 30, 2026, the reporting persons collectively beneficially owned 2,238,684 shares of OnKure Therapeutics, Inc. Class A Common Stock.
• This represents 5.5% of the class of securities outstanding.
• The filing is based on 40,496,309 shares of Common Stock outstanding as of June 30, 2026, as reported in OnKure's Form 10-Q filed on August 4, 2026.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this as a neutral filing, primarily reporting changes in beneficial ownership and indicating an exit for one reporting entity, with no new strategic or financial information.

Positives

• The filing clearly delineates the beneficial ownership of the reporting persons as of June 30, 2026.
• The reporting persons confirm that the securities were acquired and are held in the ordinary course of business and not for the purpose of influencing control.

Negatives

• The filing signifies an exit for ADAR1 Capital Management GP, LLC, which could imply a reduction in strategic interest or a shift in investment strategy.
• The specific reasons for the exit of ADAR1 Capital Management GP, LLC are not detailed.

Risks

• The filing does not contain any forward-looking statements or explicit risk factors related to OnKure Therapeutics, Inc.

Future Outlook

No forward-looking statements or guidance are provided in this filing.

Management Comments

• "By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under 240.14a-11."
• "After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct."

Industry Context

StockSavvy.ai notes that Schedule 13G filings are routine disclosures for institutional investors and significant shareholders. This particular filing indicates a change in beneficial ownership, which is common as investment strategies evolve, but it does not provide insight into the operational performance or strategic direction of OnKure Therapeutics, Inc. itself.

Comparison to Industry Standards

• This filing is a standard Schedule 13G amendment, which is a regulatory requirement for entities beneficially owning more than 5% of a class of a company's registered equity securities.
• The reporting of beneficial ownership percentages (5.5% and 4.5%) and the aggregation of holdings across different entities (ADAR1 Partners, LP, Spearhead Insurance Solutions IDF, LLC, and separately managed accounts) are typical for investment management firms.

Stakeholder Impact

• Shareholders may note the change in beneficial ownership, but the filing itself does not provide information to directly assess its impact on share price or company strategy.
• Creditors and suppliers are unlikely to be directly impacted by this ownership disclosure.

Next Steps

• ADAR1 Capital Management GP, LLC is exiting its reporting obligations.
• The filing serves as an update to beneficial ownership for ADAR1 Capital Management, LLC and Daniel Schneeberger.

Key Dates

Keywords

Schedule 13G, Beneficial Ownership, OnKure Therapeutics, ADAR1 Capital Management, SEC Filing, Common Stock, Investment Management